Literature DB >> 15280609

Pediatric tonsillopharyngitis--an evaluation of cefprozil in Indian patients.

Nomeeta Gupta1, Abhijit Mukherjee, A K Moharana.   

Abstract

OBJECTIVE: The emergence of penicillin resistant strains and the presence of co-pathogens have made the treatment of bacterial infections in children a challenge. Streptococcal tonsillopharyngitis, which is a common infection has been well treated with cefprozil, a novel third generation cephalosporin. The aim of the present study was to evaluate cefprozil in pediatric tonsillopharyngitis. An assessment of the clinical cure and bacteriological eradication rates and an overall tolerability was made.
METHODS: It was a prospective, open, non-comparative multicentric study. 316 children (mean age 6.61 years) with tonsillopharyngitis were included. Patients were given cefprozil susp 15 mg/kg/day in two divided doses a day for 10 days.
RESULTS: A clinical cure of 96.6% and bacteriological eradication of 94.29% was achieved with cefprozil. Overall tolerability of cefprozil was assessed by physicians and 46% rated tolerability of cefprozil as excellent, 38% as very good, 10% as good, 6% as fair and none as poor.
CONCLUSION: Cefprozil has been found to be an excellent drug of superior microbiological and clinical activity in the treatment of pediatric patients with tonsillopharyngitis. The drug also has an expanded spectrum.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15280609     DOI: 10.1007/BF02724119

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  10 in total

1.  Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration.

Authors:  R H Barbhaiya; U A Shukla; C R Gleason; W C Shyu; R B Wilber; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  A controlled comparative study of penicillin V and cefadroxil therapy of group A streptococcal tonsillopharyngitis.

Authors:  C M Ginsburg; G H McCracken; S D Crow; J B Steinberg; F Cope
Journal:  J Int Med Res       Date:  1980       Impact factor: 1.671

3.  A clinical experience with cefadroxil in upper respiratory tract infection.

Authors:  D M Henness
Journal:  J Antimicrob Chemother       Date:  1982-09       Impact factor: 5.790

4.  Cefprozil versus cefaclor in the treatment of acute and uncomplicated urinary tract infections. Cefprozil Multicenter Study Group.

Authors:  A Iravani; C A Doyle; S J Durham; R B Wilber
Journal:  Clin Ther       Date:  1992 Mar-Apr       Impact factor: 3.393

Review 5.  Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential.

Authors:  L R Wiseman; P Benfield
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

Review 6.  Treatment of upper and lower respiratory tract infections: clinical trials with cefprozil.

Authors:  G Aronovitz
Journal:  Pediatr Infect Dis J       Date:  1998-08       Impact factor: 2.129

7.  Cefprozil versus penicillin V in treatment of streptococcal tonsillopharyngitis.

Authors:  D Milatovic; D Adam; H Hamilton; E Materman
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

8.  Failure of penicillin to eradicate group A streptococci during an outbreak of pharyngitis.

Authors:  A S Gastanaduy; E L Kaplan; B B Huwe; C McKay; L W Wannamaker
Journal:  Lancet       Date:  1980-09-06       Impact factor: 79.321

Review 9.  Cefprozil, a new cephalosporin: its use in various clinical trials.

Authors:  R B Gainer
Journal:  South Med J       Date:  1995-03       Impact factor: 0.954

Review 10.  The role of beta-lactamase-producing bacteria in the persistence of streptococcal tonsillar infection.

Authors:  I Brook
Journal:  Rev Infect Dis       Date:  1984 Sep-Oct
  10 in total
  1 in total

Review 1.  Redefining the management of pediatric tonsillopharyngitis with cefprozil.

Authors:  Nameet Jerath; Ganesh Shetty
Journal:  Indian J Pediatr       Date:  2007-12       Impact factor: 1.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.